BUPIVACAINE LIPOSOME Drug Patent Profile

« Back to Dashboard

Which patents cover Bupivacaine Liposome, and what generic alternatives are available?

Bupivacaine Liposome is a drug marketed by Hengrui Pharma and is included in one NDA.

The generic ingredient in BUPIVACAINE LIPOSOME is bupivacaine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the bupivacaine profile page.

Summary for BUPIVACAINE LIPOSOME

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	67
Patent Applications:	4,798
DailyMed Link:	BUPIVACAINE LIPOSOME at DailyMed

Recent Clinical Trials for BUPIVACAINE LIPOSOME

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hainan Medical College	PHASE2
The Second Affiliated Hospital of Hainan Medical University	PHASE2
Second Affiliated Hospital, School of Medicine, Zhejiang University	EARLY_PHASE1

See all BUPIVACAINE LIPOSOME clinical trials

Pharmacology for BUPIVACAINE LIPOSOME

Drug Class	Amide Local Anesthetic
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for BUPIVACAINE LIPOSOME

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348-001	Jul 1, 2024		DISCN	No	No
Hengrui Pharma	BUPIVACAINE LIPOSOME	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	214348-002	Jul 1, 2024		DISCN	No	No

Bupivacaine Liposome Market Dynamics, Financial Trajectory, Patents, and Generic Risk

Last updated: October 15, 2026

Liposomal bupivacaine, marketed primarily as Exparel by Pacira BioSciences, is a premium extended-release local anesthetic used for postoperative pain control. Its commercial position rests on hospital adoption, opioid-sparing protocols, expanded nerve-block indications, and a delivery system that extends bupivacaine exposure beyond conventional formulations. The main risks are high acquisition cost, variable clinical value by procedure, competing long-acting analgesics, and potential generic entry after Orange Book patent challenges.

Pacira’s Exparel franchise grew from a niche surgical analgesic into the company’s core revenue asset. Revenue expansion has depended more on procedure penetration and label expansion than on price increases. The product remains commercially durable, but its risk profile is shifting from clinical adoption risk toward patent, reimbursement, and generic-entry risk.

What is liposomal bupivacaine and how does Exparel work?

Liposomal bupivacaine is a multivesicular liposome formulation of bupivacaine designed to release the active ingredient over an extended period after local administration. Exparel is supplied as a preservative-free injectable suspension and is administered into the surgical site or by selected peripheral nerve-block techniques.

The formulation is intended to reduce the frequency and intensity of postoperative pain and may reduce rescue opioid use. Its clinical value varies by procedure, surgical technique, baseline pain burden, and the use of multimodal analgesia.

FDA-approved indications

The FDA originally approved Exparel in 2011 for single-dose infiltration into the surgical site in adults. The label later expanded to include:

FDA milestone	Product development
2011	Adult local administration for postoperative analgesia
2018	Pediatric infiltration indication for patients aged 6 years and older
2021	Interscalene brachial plexus nerve block in adults
2023	Adductor canal block in adults

The product is not interchangeable with ordinary bupivacaine hydrochloride. The label includes specific administration, dilution, compatibility, and nerve-block restrictions. The FDA label also warns against certain routes of administration, including intravascular, intrathecal, and epidural administration.[1]

How large is the liposomal bupivacaine market?

The addressable market is the hospital and ambulatory surgical center market for postoperative local analgesia. The relevant competitive set includes:

• Generic bupivacaine hydrochloride.
• Ropivacaine.
• Liposomal bupivacaine products.
• Bupivacaine-meloxicam combinations such as Zynrelef.
• Continuous peripheral nerve-block catheters.
• Nonopioid multimodal regimens using acetaminophen, NSAIDs, corticosteroids, and regional anesthesia.

Exparel occupies the premium end of the local-anesthetic market. Conventional bupivacaine is inexpensive and familiar, while Exparel requires hospitals to justify a substantially higher acquisition cost through reduced opioid use, shorter recovery, fewer nursing interventions, improved patient throughput, or reduced post-discharge resource use.

Market growth drivers

The principal growth drivers are:

1. Expansion of outpatient orthopedic, plastic, general, gynecologic, and colorectal surgery.
2. Greater use of enhanced recovery after surgery protocols.
3. Hospital and payer pressure to reduce opioid exposure.
4. Increased use of regional anesthesia outside traditional inpatient settings.
5. Broader use of adductor canal and interscalene nerve blocks.
6. Pacira’s physician education and hospital-account strategy.

The strongest commercial opportunity is in procedures with predictable acute postoperative pain and a clear economic benefit from reducing rescue medication, observation time, or unplanned care.

Market constraints

Adoption is limited by the product’s price premium and inconsistent evidence across surgical procedures. Exparel may produce a clinically useful duration of analgesia in some settings, but trial results have not established uniform superiority over all conventional multimodal regimens. Hospitals also face budget scrutiny because drug acquisition cost is visible immediately, while potential savings may accrue elsewhere in the care pathway.

What is the financial trajectory of liposomal bupivacaine?

Exparel is Pacira BioSciences’ principal commercial product and has generated the majority of the company’s product revenue. Pacira also commercializes Zilretta, an extended-release triamcinolone acetonide product for osteoarthritis pain, but Exparel remains the central driver of corporate performance.

Pacira revenue trajectory

Reported figures below are based on Pacira annual filings and company disclosures. Exparel net product sales are shown where separately reported; total product revenue includes other commercial products.

Fiscal year	Exparel commercial position	Financial trend
2019	Established hospital product with expanding surgical use	Continued growth before the pandemic
2020	Elective-surgery disruption	Revenue affected by COVID-19 procedure volume reductions
2021	Recovery in surgical volumes and expanded nerve-block labeling	Strong rebound
2022	Broader penetration in orthopedic and outpatient procedures	Continued growth, with hospital purchasing pressure
2023	Mature anchor product with expanded label and commercial reach	Exparel remained the dominant revenue contributor

Pacira reported Exparel net product sales of approximately $681 million in 2023, compared with approximately $652 million in 2022, according to the company’s 2023 Form 10-K.[2] The increase reflected procedure-volume recovery, adoption of nerve-block uses, and account penetration rather than a fundamental change in the product’s pricing model.

Margin and cash-flow considerations

Exparel has the economics of a specialty injectable rather than a commodity generic. Its gross-margin profile benefits from branded pricing and proprietary manufacturing, but profitability is affected by:

• Sales-force costs directed at surgeons, anesthesiologists, and hospitals.
• Clinical education and evidence-generation expenses.
• Manufacturing scale and liposome production complexity.
• Contracting concessions to hospital systems.
• Litigation and patent-defense costs.
• Research spending on additional indications and delivery technologies.

The product’s commercial value is high because Pacira does not need to win the entire local-anesthetic market. It needs to maintain a defensible share of high-volume surgical procedures where the premium price can be linked to measurable clinical or economic outcomes.

When does Exparel lose exclusivity?

Exparel does not have one single exclusivity date. Market protection depends on separate layers of FDA regulatory exclusivity, listed patents, pediatric exclusivity, formulation claims, manufacturing claims, and the timing of any generic approval.

Regulatory exclusivity

Exparel’s original approval in 2011 included five-year new chemical entity exclusivity. That period expired before the current commercial risk period. Pediatric exclusivity associated with later label expansion does not recreate the original five-year exclusivity period for the entire product.

The principal present risk is patent-based rather than new-chemical-entity exclusivity.

Orange Book patents

The FDA Orange Book has listed patents associated with Exparel, including patents covering liposomal bupivacaine compositions and related formulation technology. Patent records and expiration dates can change through patent-term adjustment, patent-term extension, terminal disclaimers, reexamination, post-grant proceedings, and litigation outcomes.

Key patent-estate categories include:

Protection category	Commercial purpose
Liposomal composition claims	Protect the multivesicular delivery system containing bupivacaine
Particle and formulation claims	Protect formulation characteristics associated with extended release
Manufacturing claims	Increase the difficulty of reproducing the product consistently
Method-of-use claims	Cover administration in specific surgical or nerve-block settings
Device or administration claims	Protect delivery approaches and use conditions where applicable

Pacira has also pursued patents covering later-approved uses. Method-of-use patents generally provide narrower protection than composition claims because a generic applicant may attempt to carve out a protected indication through a Section viii statement.

The most important commercial question is whether a generic applicant can obtain approval for an unprotected use while avoiding infringement of formulation and manufacturing claims. That analysis depends on the exact Orange Book listing and the ANDA applicant’s proposed label.

Which companies are challenging Exparel patents?

Generic injectable manufacturers have a commercial incentive to challenge Exparel because the product has substantial annual revenue and a materially higher price than conventional bupivacaine. Publicly reported patent disputes have involved generic-drug companies seeking to market bupivacaine liposome injectable suspension.

The relevant risk categories are:

• Paragraph IV certifications asserting that listed patents are invalid, unenforceable, or not infringed.
• Declaratory-judgment actions.
• Hatch-Waxman infringement suits filed within 45 days of a Paragraph IV notice.
• Settlement agreements that establish a licensed or otherwise agreed generic-entry date.
• FDA approval subject to a label carve-out.
• At-risk launch before final patent resolution.

A Paragraph IV notice does not establish generic entry. If the patent holder files an infringement action within the statutory period, FDA approval is generally subject to a 30-month stay, subject to statutory exceptions and court developments.[3]

Litigation and settlement economics

The outcome of Exparel litigation will depend on claim construction, written-description and enablement challenges, obviousness arguments, manufacturing reproducibility, and the scope of the proposed generic label.

A settlement can preserve significant branded revenue if it delays generic entry until late in the patent term. The settlement may also include a license, supply arrangement, or launch date that is earlier than patent expiration but later than the generic company’s preferred entry date. The economic value of an agreed entry date is high because Exparel is Pacira’s principal revenue source.

What generic entry risks exist for liposomal bupivacaine?

Generic entry would likely produce a rapid price reduction, but the effect may differ from ordinary small-molecule tablet markets. Liposomal bupivacaine is an injectable complex formulation with manufacturing and quality-control requirements that may limit the number of successful entrants.

Technical barriers to generic competition

A competing product must demonstrate more than the presence of bupivacaine. It must address:

• Liposome size and distribution.
• Internal architecture of the multivesicular system.
• Drug loading and encapsulation.
• Release kinetics.
• Particle stability.
• Sterility and injectable quality.
• Batch-to-batch reproducibility.
• Pharmacokinetic and, where required, clinical comparability.

These requirements can increase development cost and delay commercial launch. They do not eliminate generic risk because an ANDA applicant can challenge patents and seek approval under FDA standards applicable to complex injectable products.

Generic launch scenarios

Scenario	Likely commercial effect
No approved generic before core patent expiry	Exparel retains premium pricing and hospital-contract leverage
Single generic with limited launch	Moderate price pressure and selective hospital substitution
Multiple approved generics	Rapid price erosion and loss of formulary exclusivity
At-risk launch	Immediate litigation and potential damages exposure
Label-carved generic	Competition in unprotected indications while branded uses remain protected

The highest-risk scenario for Pacira is multiple generic approvals combined with hospital acceptance of therapeutic substitution. The lowest-risk scenario is delayed or limited generic entry caused by unresolved formulation and manufacturing patents.

How does Exparel compare with Zynrelef and conventional bupivacaine?

Attribute	Exparel	Zynrelef	Conventional bupivacaine
Active ingredients	Liposomal bupivacaine	Bupivacaine plus meloxicam	Bupivacaine
Release profile	Extended release from liposomal system	Extended local delivery with NSAID component	Shorter duration
Main use	Surgical-site infiltration and selected nerve blocks	Postsurgical local analgesia	Infiltration, nerve blocks, epidural and other established uses
Price position	Premium	Premium	Low-cost generic
Clinical adoption barrier	Acquisition cost and variable evidence	Formulation and protocol adoption	Limited duration
Patent risk	Composition, formulation, use, and manufacturing claims	Combination and delivery patents	Mature generic market
Commercial owner	Pacira BioSciences	Heron Therapeutics	Multiple generic manufacturers

Exparel has a broader commercial base and longer market history than Zynrelef. Zynrelef may compete in surgical-site analgesia, while Exparel has strengthened its position through peripheral nerve-block indications. Conventional bupivacaine remains the economic benchmark and is difficult to displace where hospitals prioritize acquisition cost over incremental recovery benefits.

What is the FDA and Orange Book status of Exparel?

Exparel is an FDA-approved prescription injectable product under NDA 022496. It is listed in the FDA Orange Book as a prescription drug with patent information submitted by the innovator.[1][4]

The most important regulatory issues are:

• Whether listed patents remain enforceable.
• Whether patents cover all approved uses or only specific methods.
• Whether an ANDA applicant can use a Section viii carve-out.
• Whether FDA approval is delayed by a statutory patent stay.
• Whether a generic product is therapeutically substitutable at the hospital level.
• Whether the generic label includes all major commercial indications.

Orange Book listing does not itself prove that a patent will survive litigation. It identifies patents that the NDA holder has submitted for listing and provides the framework for patent certifications by ANDA applicants.

What geographic coverage and manufacturing IP protect the product?

The commercial franchise is strongest in the United States, where Exparel has its principal approval, market access, and patent litigation exposure. International opportunity is narrower because regulatory approvals, reimbursement systems, patent rights, and hospital purchasing practices differ by country.

Manufacturing intellectual property may be commercially significant even when composition claims approach expiration. A complex liposomal injectable requires specialized production controls, sterile processing, analytical testing, and scale-up capability. Manufacturing patents can raise the cost of entry, but trade secrets and process know-how may be equally important and are not fully visible in public patent databases.

Geographic risk depends on:

• National patent-term differences.
• Local regulatory pathways for complex injectables.
• Reference-product requirements.
• Hospital tender systems.
• Reimbursement for postoperative analgesia.
• Local availability of conventional bupivacaine and alternative long-acting products.

What is the revenue exposure if generic Exparel launches?

Exparel represents the majority of Pacira’s commercial revenue. A successful generic launch would affect Pacira through lower volume, lower net price, contracting pressure, and possible loss of hospital formulary preference.

A simplified revenue-impact framework is:

Generic penetration	Potential branded impact
10% to 20%	Price concessions and limited volume loss
25% to 40%	Material revenue decline with pressure on gross margin
50% or more	Franchise-level erosion and restructuring of commercial spending
Broad substitution	Loss of premium pricing and reduced return on lifecycle investments

The actual impact would depend on the number of entrants, generic launch timing, distribution access, hospital substitution rules, clinical differentiation, and the ability of Pacira to shift demand toward protected nerve-block uses or next-generation products.

How strong is the patent estate for liposomal bupivacaine?

The estate is stronger than a single composition patent but weaker than a biologic franchise protected by manufacturing complexity, regulatory exclusivity, and multiple platform patents. Its strength lies in the interaction of:

• Complex liposomal formulation claims.
• Manufacturing and quality-control barriers.
• Long clinical experience.
• Multiple approved administration routes.
• Hospital protocols and physician familiarity.
• Potential method-of-use patents.

Its weaknesses are:

• The age of the original approval.
• Exposure to Paragraph IV litigation.
• The ability to challenge obviousness and enablement.
• Potential label carving.
• A low-cost conventional bupivacaine alternative.
• Clinical evidence that varies by procedure.

The estate should be viewed as commercially meaningful but not immune to generic erosion.

Key Takeaways

• Liposomal bupivacaine, sold as Exparel, is Pacira BioSciences’ main commercial asset.
• The product competes against inexpensive generic bupivacaine, Zynrelef, ropivacaine, and multimodal postoperative pain protocols.
• Revenue growth has been driven by surgical-volume recovery, hospital penetration, and expanded nerve-block indications.
• Exparel’s main protection is patent-based because original FDA exclusivity has expired.
• Formulation, manufacturing, and method-of-use patents create barriers but do not eliminate Paragraph IV risk.
• Generic entry could cause rapid price erosion, especially if multiple manufacturers obtain approval.
• Manufacturing complexity may delay competition and limit the number of viable entrants.
• Pacira’s financial exposure is high because Exparel accounts for most of its product revenue.
• The most important diligence items are current Orange Book listings, pending Paragraph IV litigation, settlement terms, and the scope of any generic label carve-out.

FAQs about bupivacaine liposome patents and market competition

Is Exparel the same as ordinary bupivacaine?

No. Exparel contains bupivacaine in a multivesicular liposomal delivery system. Conventional bupivacaine is a non-liposomal immediate-release injectable.

Can a generic company copy Exparel without copying the brand formulation?

A generic applicant must demonstrate pharmaceutical equivalence and meet FDA requirements for the applicable approval pathway. Patent infringement may still arise from formulation, manufacturing, or method-of-use claims even if the proposed product uses different manufacturing steps.

Does Exparel have biosimilar risk?

No. Exparel is a complex injectable small-molecule formulation, not a biologic. Competition would arise through generic or other abbreviated pathways rather than biosimilar approval.

Which procedures generate the most commercial value for Exparel?

High-volume orthopedic, abdominal, colorectal, plastic, and outpatient procedures are important markets. Commercial value is highest where extended local analgesia can reduce opioid use, improve recovery, or support same-day discharge.

What would protect Pacira after generic Exparel entry?

Pacira could retain value through protected indications, clinical preference, hospital contracts, manufacturing advantages, lifecycle products, new delivery technologies, and evidence supporting economic benefits in selected procedures.

References

1. U.S. Food and Drug Administration. (2023). Exparel (bupivacaine liposome injectable suspension) prescribing information.
2. Pacira BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023.
3. U.S. Food and Drug Administration. (2024). Generic drug user fees and the ANDA patent certification process.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.